Insulet Beats Q3 Targets and Lifts 2025 Outlook on Surging Omnipod Sales

Overview

• Revenue rose to $706.3 million with profit of $87.6 million for the quarter ended Sept. 30, as adjusted earnings reached $1.24 per share versus $1.14 expected.
• Omnipod generated $699.2 million in sales, up 31% year over year, including 25.6% growth in the U.S. and 46.5% internationally.
• Insulet now projects full-year revenue growth of 28% to 29%, raised from prior guidance of 24% to 27%.
• The company expects Omnipod sales to increase 29% to 30% for the year, up from a previous 25% to 28% outlook.
• Management recently redeemed the remaining $380 million principal of convertible notes, simplifying the capital structure and limiting potential dilution.